Plain-English translation of NCT07077213 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing a new imaging agent called 18F-FAPI-74 combined with PET/CT scans to detect scarring and fibrosis in the lungs of people with tuberculosis. This medication is injected into the bloodstream before the scan, and the scan can show where lung damage has occurred. The goal is to develop a better, noninvasive way to assess how TB affects the lungs during and after treatment.
Current imaging methods may not detect all the lung scarring and damage that TB can cause. This trial aims to see if the new imaging agent can reveal this damage more sensitively, which could help doctors better understand and manage TB-related lung disease.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive an injection of the imaging medication into your vein, followed by a PET/CT scan (a combination imaging test). You may have scans at the beginning of TB treatment and again after completing treatment, allowing doctors to compare how your lungs change. The entire process involves visits to the hospital or clinic for imaging, blood draws, and follow-up visits to monitor your health and TB treatment progress.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Sponsor
Children's Hospital Medical Center, Cincinnati
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
Enrollment target
~30 participants
Started
March 2026
Primary completion
July 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sanjay K Jain, MD
Children's Hospital Medical Center, Cincinnati
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.